A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

NCT03505554 | Unknown Phase 2

• 1 other identifier: CRU3
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.

Conditions

Anaplastic Large Cell Lymphoma, ALK-Positive

Keywords

ALK; relapsed; lorlatinib

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate

  ORR

  1 year

Secondary Outcomes (5)

• Progression Free Survival

  1 year

• Overall Survival

  1 year

• toxicity

  up to 24 months

• Quality of life

  up to 24 months

• Study the mutational status of ALK pre/post Lorlatinib

  up to 24 months

Study Arms (1)

Lorlatinib

EXPERIMENTAL

100 mg QD

Drug: Lorlatinib

Interventions

Lorlatinib DRUG

100 mg QD

Also known as: PF-06463922

Lorlatinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed and dated Informed Consent approved by Local Ethical Committee before any protocol-specific screening procedures.
• ALK+ Lymphoma diagnosed by IHC or FISH.
• Refractory disease or relapse after at least one prior chemotherapy regimen (typically a minimum of 6 cycles of CHOP) and at least one ALK inhibitor; presence of measurable disease by physical examination, CT or CT-PET scan.
• Any prior antitumor medical treatment or major surgeries must have been completed at least 14 days prior to initiation of study medication. This could not be respected if there is clear evidence of disease progression, manifested as growing pain attributable to the tumour, fever, growing tumour lesions, increasing LDH values. Systemic anti-cancer therapy completed within a minimum of 5 half-lives of study entry.
• Able to take oral therapy.
• Female or male, 18 years of age or older.
• ECOG performance status 0-3.
• Adequate organ function as defined by the following criteria:
• Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy Total serum bilirubin 1.5 x ULN (except patients with documented Gilbert's syndrome Creatinine ≤ 1.5 x ULN.
• Adequate bone marrow function:
• Absolute neutrophil count (ANC) ≥ 1000/µL Platelets ≥ 50.000/µL Hemoglobin ≥ 9.0 g/dL The hematological values will not be considered in case of bone marrow involvement.
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
• Female and male patients who are of childbearing potential must agree to use an effective form of contraception (2 forms of contraception) with their partners throughout participation in this study and for at least 90 days after the last dose of treatment.

You may not qualify if:

• Current treatment on another therapeutic clinical trial.
• Clinically significant cardiovascular disease (that is, active or \<3 months prior to enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II)
• Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2: second-degree or third-degree AV block (unless paced) or any AV block with PR \>220 msec, uncontrolled atrial fibrillation of any grade, bradycardia defined as \<50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc \>470 msec, or congenital long QT syndrome.
• Pregnancy or breastfeeding.
• Use of drugs or foods that are known strong or moderate CYP3A4 inhibitors, inducers and substrates; drugs that are CYP2C9 substrates; drugs that are strong CYP2C19 inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp substrates.
• Prior malignancy other than basal cell carcinoma , if original diagnosis happened in the last 5 years.
• Patients with predisposing characteristics for acute pancreatitis according to investigator judgment (e.g. uncontrolled hyperglycemia, current gallstone disease, alcoholism).
• Hypertriglyceridemia ≥ grade 1.
• Active and clinically significant bacterial, fungal, or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.
• Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration.

Sponsors & Collaborators

• University of Milano Bicocca: lead
• Pfizer: collaborator

Study Sites (2)

Asst-Monza

Monza, Italy/MB, 20900, Italy

RECRUITING

UOC Ematologia, Ospedale S. Eugenio

Roma, Italy

RECRUITING

MeSH Terms

Conditions

Lymphoma, Large-Cell, Anaplastic; Recurrence

Interventions

lorlatinib

Condition Hierarchy (Ancestors)

Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• CARLO GAMBACORTI-PASSERINI, MD

  University of Milano Bicocca

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Silvia Mori, PhD

CONTACT

+390392339277; silvia.mori@unimib.it

Silvia Baretta, SC

CONTACT

+390392339743; silvia.baretta1@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2018
• First Posted: April 23, 2018
• Study Start: October 10, 2017
• Primary Completion: December 1, 2024
• Study Completion: December 1, 2024
• Last Updated: August 7, 2023

Record last verified: 2023-08

Locations

IT (2)